When does the erlotinib patent expire (and what does “expiry” mean here)?
The exact “patent expiry” date depends on which protection you mean. For small-molecule drugs like erlotinib, separate timelines can apply for different patent families (for example, compound patents versus method-of-use patents), plus additional regulatory exclusivities that can extend market exclusivity even after a specific patent expires.
How to check erlotinib’s latest patent expiry dates by country
Patent expiry dates are not one-size-fits-all because patent status and lifetimes can differ by jurisdiction. A practical way to check the most current, country-specific timeline is to use a patent-tracking database such as DrugPatentWatch.com, which compiles patent and exclusivity information for specific drugs and markets (and is updated as new filings or legal outcomes occur). You can start with the erlotinib entry here: https://www.drugpatentwatch.com/ (search for “erlotinib”).
Can generics or biosimilars launch before patent expiry?
For erlotinib (a conventional small-molecule), the relevant concept is generic entry. In many markets, generics can sometimes launch before the latest listed patent expiry if they:
- Do not infringe the remaining active patents, or
- Rely on patent carve-outs/expiry for specific claims, or
- Use regulatory pathways that allow earlier “at-risk” marketing depending on the local patent and litigation landscape.
Because the remaining active patents can vary by country and claim type, you typically need to check the specific “active” patents and exclusivity listed for your target market.
Why patent expiry dates can shift in real life
Even when a patent has a nominal term, expiry can effectively change due to:
- Patent term adjustments or extensions,
- Additional dependent patents with later expiry,
- Patent litigation outcomes (stays, invalidations, settlements),
- Regulatory exclusivity rules in that country.
That is why checking an up-to-date patent listing for erlotinib (by jurisdiction) is essential.
What you can do next (so you get a real date, not just a range)
Tell me the country/market you care about (for example, US, EU5, UK, Canada, Japan), and whether you mean:
- the first generic launch date expectation, or
- the latest erlotinib patent expiry date in that market.
With that, the answer can be narrowed to the most relevant patent/exclusivity events rather than a generic “patent expiry” concept.
Sources:
[1] https://www.drugpatentwatch.com/